Download PDF
Thromb Haemost 1999; 82(02): 305-311
DOI: 10.1055/s-0037-1615847
Research Article
Schattauer GmbH

Mechanisms of Signaling through Urokinase Receptor and the Cellular Response

Yuri Koshelnick
1   Department of Vascular Biology and Thrombosis Research
,
Monika Ehart
1   Department of Vascular Biology and Thrombosis Research
,
Hannes Stockinger
2   Institute of Immunology; Vienna International Research Cooperation Center at NFI, University of Vienna, AUSTRIA
,
Bernd R. Binder
1   Department of Vascular Biology and Thrombosis Research
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

The urokinase-urokinase receptor (u-PA-u-PAR) system seems to play a crucial role in a number of biological processes, including local fibrinolysis, tumor invasion, angiogenesis, neointima and atherosclerotic plaque formation, inflammation, and matrix remodeling during wound healing and development.1-6 Binding of urokinase to its specific receptor provides cells with a localized proteolytic potential. It stimulates conversion of cell surface-bound plasminogen into active plasmin, which, in turn, is required for proteolytic degradation of basement membrane components, including fibronectin, collagen, laminin, and proteoglycan core proteins.7 Moreover, plasmin activates other matrix-degrading enzymes, such as matrix metalloproteinases.8 Overexpression of u-PA/u-PAR correlates with tumor invasion and metastasis formation,9-13 while reduction of cell-surface bound u-PA and inhibition of u-PAR expression leads to a significant decrease of invasive and metastatic activity.14 Specific antagonists that suppress binding of u-PA to u-PAR have been shown to inhibit cell-surface plasminogen activation, tumor growth, and angiogenesis both in vitro and in vivo models.15,16

Independently of its proteolytic activity, u-PA is implicated in many biological processes that seem to require u-PAR-mediated intracellular signal transduction, such as proliferation, chemotactic movement and adhesion, migration, and differentiation.17 Data obtained in the late 1980s indicated that u-PA not only provides cells with local proteolytic activity, but might also be capable of transducing signals to the cell.18-22 At that time, however, the u-PAR has just been isolated, cloned, and identified as a glycosylphosphatidylinositol (GPI)-linked protein and not a transmembrane protein. Signaling via the u-PAR was, therefore, regarded as being unlikely, and the effects of u-PA on cell proliferation18-22 were thought to be mediated by proteolytic activation of latent growth factors. The assumption of direct signaling via u-PAR was, in fact, considered controversial, until about 10 years later when a physical association between u-PAR and signaling proteins was found.23 From this report on, several proteins associated with u-PAR have been identified. Now, u-PAR seems to be part of a large “signalosome” associated and interacting with several proteins on both the outside and inside of the cell.

 

  • References

  • 1 Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol. 1987; 104: 801-804.
    CrossrefPubMedGoogle Scholar
  • 2 Binder BR. Influence of urokinase on cell proliferation and invasion. Blood Coagul Fibrinolysis. 1990; 1: 717-720.
    PubMedGoogle Scholar
  • 3 Dano K, Andreasen PA, Grondahl HJ, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985; 44: 139-266.
    PubMedGoogle Scholar
  • 4 Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol. 1988; 4: 93-126.
    CrossrefPubMedGoogle Scholar
  • 5 Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980; 43: 77-89.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Kirchheimer JC, Binder BR. Function of receptor-bound urokinase. Semin Thromb Hemost. 1991; 17: 246-250.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Moser TL, Enghild JJ, Pizzo SV, Stack MS. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. J Biol Chem. 1993; 268: 18917-18923.
    PubMedGoogle Scholar
  • 8 Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci. 1992; 667: 1-12.
    CrossrefPubMedGoogle Scholar
  • 9 Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72: 1-22.
    CrossrefPubMedGoogle Scholar
  • 10 Kim J, Yu W, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semi-quantitative PCR-based assay. Cell. 1998; 94: 353-362.
    CrossrefPubMedGoogle Scholar
  • 11 Bruckner A, Filderman AE, Kirchheimer JC, Binder BR, Remold HG. Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. Cancer Res. 1992; 52: 3043-3047.
    PubMedGoogle Scholar
  • 12 Kirchheimer JC, Pfluger H, Hienert G, Binder BR. Increased urokinase activity to antigen ratio in human renal-cell carcinoma. Int J Cancer. 1985; 35: 737-741.
    CrossrefPubMedGoogle Scholar
  • 13 Kirchheimer JC, Pfluger H, Ritschl P, Hienert G, Binder BR. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis. 1985; 5: 344-355.
    PubMedGoogle Scholar
  • 14 Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA. 1993; 90: 5021-5025.
    CrossrefPubMedGoogle Scholar
  • 15 Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton TJ, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996; 56: 2428-2433.
    PubMedGoogle Scholar
  • 16 Li H, Lu H, Griscelli F, Opolon P, Sun LQ, Ragot T, Legrand Y, Belin D, Soria J, Soria C, Perricaudet M, Yeh P. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 1998; 5: 1105-1113.
    CrossrefPubMedGoogle Scholar
  • 17 Gyetko MR, Todd RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest. 1994; 93: 1380-1387.
    CrossrefPubMedGoogle Scholar
  • 18 Kirchheimer JC, Christ G, Binder BR. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem. 1989; 181: 103-107.
    CrossrefPubMedGoogle Scholar
  • 19 Kirchheimer JC, Wojta J, Christ G, Binder BR. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA. 1989; 86: 5424-5428.
    CrossrefPubMedGoogle Scholar
  • 20 Kirchheimer JC, Wojta J, Christ G, Binder BR. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J. 1987; 1: 125-128.
    CrossrefPubMedGoogle Scholar
  • 21 Kirchheimer JC, Wojta J, Christ G, Hienert G, Binder BR. Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells. Carcinogenesis. 1988; 9: 2121-2123.
    CrossrefPubMedGoogle Scholar
  • 22 Kirchheimer JC, Wojta J, Hienert G, Christ G, Heger ME, Pfluger H, Binder BR. Effect of urokinase on the proliferation of primary cultures of human prostatic cells. Thromb Res. 1987; 48: 291-298.
    CrossrefPubMedGoogle Scholar
  • 23 Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995; 181: 1381-1390.
    CrossrefPubMedGoogle Scholar
  • 24 Ellis V, Dano K. Potentiation of plasminogen activation by an anti-urokinase monoclonal antibody due to ternary complex formation. A mechanistic model for receptor-mediated plasminogen activation. J Biol Chem. 1993; 268: 4806-4813.
    PubMedGoogle Scholar
  • 25 Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA. 1985; 82: 4939-4943.
    CrossrefPubMedGoogle Scholar
  • 26 Jorg M, Binder BR. Kinetic analysis of plasminogen activation by purified plasma kallikrein. Thromb Res. 1985; 39: 323-331.
    CrossrefPubMedGoogle Scholar
  • 27 Ugwu F, Van HB, Bini A, Collen D, Lijnen HR. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry. 1998; 37: 7231-7236.
    CrossrefPubMedGoogle Scholar
  • 28 Behrendt N, Ronne E, Dano K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler. 1995; 376: 269-279.
    PubMedGoogle Scholar
  • 29 Franco P, Massa O, Garcia-Rocha M, Chiaradonna F, Iaccarino C, Correas I, Mendez E, Avila J, Blasi F, Stopelli MP. Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J Biol Chem. 1998; 273: 27734-27740.
    CrossrefPubMedGoogle Scholar
  • 30 Stahl A, Mueller BM. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol. 1995; 129: 335-344.
    CrossrefPubMedGoogle Scholar
  • 31 Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998; 58: 1843-1849.
    PubMedGoogle Scholar
  • 32 Treister A, Sagi-Assif O, Meer M, Smorodinsky NI, Anavi R, Golan I, Meshel T, Kahana O, Eshel R, Katz BZ, Shevach E, Witz IP. Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress. Int J Cancer. 1998; 77: 306-313.
    CrossrefPubMedGoogle Scholar
  • 33 Mao M, Yu M, Tong JH, Ye J, Zhu J, Huang QH, Fu G, Yu L, Zhao SY, Waxman S, Lanotte M, Wang ZY, Tan JZ, Chan SJ, Chen Z. RIG-E, a human homolog of the murine Ly-6 family, is induced by retinoic acid during the differentiation of acute promyelocytic leukemia cell. Proc Natl Acad Sci USA. 1996; 93: 5910-5914.
    CrossrefPubMedGoogle Scholar
  • 34 Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J Cell Biol. 1996; 134: 1563-1571.
    CrossrefPubMedGoogle Scholar
  • 35 Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res. 1996; 224: 344-353.
    CrossrefPubMedGoogle Scholar
  • 36 Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994; 269: 32380-32388.
    PubMedGoogle Scholar
  • 37 Hoyer HG, Behrendt N, Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1997; 420: 79-85.
    CrossrefPubMedGoogle Scholar
  • 38 Germer M, Kanse SM, Kirkegaard T, Kjoller L, Felding-Habermann B, Goodman S, Preissner KT. Kinetic analysis of integrin-dependent cell adhesion on vitronectin—The inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. Eur J Biochem. 1998; 253: 669-674.
    CrossrefPubMedGoogle Scholar
  • 39 Seiffert D, Ciambrone G, Wagner NV, Binder BR, Loskutoff DJ. The somatomedin B domain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem. 1994; 269: 2659-2666.
    PubMedGoogle Scholar
  • 40 Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997; 100: 58-67.
    CrossrefPubMedGoogle Scholar
  • 41 Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer. 1997; 71: 116-122.
    CrossrefPubMedGoogle Scholar
  • 42 Sitrin RG, Todd RF, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest. 1996; 97: 1942-1951.
    CrossrefPubMedGoogle Scholar
  • 43 Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91: 2305-2312.
    PubMedGoogle Scholar
  • 44 Colman RW, Pixley RA, Najamunnisa S, Yan W, Wang J, Mazar A, McCrae KR. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest. 1997; 100: 1481-1487.
    CrossrefPubMedGoogle Scholar
  • 45 Ehart M, Koshelnick Y, Stockinger H, Binder BR. Interactions of uPAR: impact on receptor regulation and signal transduction. Fibrinol Proteol. 1998; 12: 211-217.
    CrossrefPubMedGoogle Scholar
  • 46 Ruthner M, Koshelnick Y, Binder BR. Signal transduction and biologic effects induced by crosslinking of receptor-bound urokinase in the human kidney epithelial cell line TCL-598. Fibrinolysis. 1996; 10 (Suppl. 03) 49a.
    PubMedGoogle Scholar
  • 47 Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem. 1997; 272: 28563-28567.
    CrossrefPubMedGoogle Scholar
  • 48 Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, Gulba DC. The JAK/STAT pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem. 1998; 273: 315-321.
    CrossrefPubMedGoogle Scholar
  • 49 Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol. 1997; 9: 714-724.
    CrossrefPubMedGoogle Scholar
  • 50 Shaya S, Kindzelskii AL, Minor J, Moore EC, Todd RF, Petty HR. Aberrant integrin (CR4; alpha(x)beta2; CD11c/CD18) oscillations on neutrophils in a mild form of pyoderma gangrenosum. J Invest Dermatol. 1998; 111: 154-158.
    CrossrefPubMedGoogle Scholar
  • 51 Kindzelskii AL, Eszes MM, Todd RF, Petty HR. Proximity oscillations of complement type 4 (alphaX beta2) and urokinase receptors on migrating neutrophils. Biophys J. 1997; 73: 1777-1784.
    CrossrefPubMedGoogle Scholar
  • 52 Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne E, Kobzik L, Chapman HA. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996; 88: 3185-3194.
    PubMedGoogle Scholar
  • 53 Cao D, Mizukami IF, Garni WB, Kindzelskii AL, Todd RF, Boxer LA, Petty HR. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium. J Immunol. 1995; 154: 1817-1829.
    PubMedGoogle Scholar
  • 54 Xue W, Kindzelskii AL, Todd RF, Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol. 1994; 152: 4630-4640.
    PubMedGoogle Scholar
  • 55 Xue W, Mizukami I, Todd RF, Petty HR. Urokinase-type plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997; 57: 1682-1689.
    PubMedGoogle Scholar
  • 56 Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.
    CrossrefPubMedGoogle Scholar
  • 57 Yebra M, Parry GN, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem. 1996; 271: 29393-29399.
    CrossrefPubMedGoogle Scholar
  • 58 Nykjaer A, Petersen CM, Moller B, Jensen PH, Moestrup SK, Holtet TL, Etzerodt M, Thogersen HC, Munch M, Andreasen PA. et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem. 1992; 267: 14543-14546.
    PubMedGoogle Scholar
  • 59 Stefansson S, Muhammad S, Cheng XF, Battey FD, Strickland DK, Lawrence DA. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein. J Biol Chem. 1998; 273: 6358-6366.
    CrossrefPubMedGoogle Scholar
  • 60 Goretzki L, Mueller BM. Low-density-lipoprotein-receptor-related protein (LRP) interacts with a GTP-binding protein. Biochem J. 1998; 336: 381-386.
    CrossrefPubMedGoogle Scholar
  • 61 Tsuchiya H, Katsuo S, Matsuda E, Sunayama C, Tomita K, Ueda Y, Binder BR. The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. Gen Diagn Pathol. 1995; 141: 41-48.
    PubMedGoogle Scholar
  • 62 Plas E, Carroll VA, Jilch R, Mihaly J, Vesely M, Ulrich W, Pfluger H, Binder BR. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer. Int J Cancer. 1998; 78: 320-325.
    CrossrefPubMedGoogle Scholar
  • 63 Nykjaer A, Christensen EI, Vorum H, Hager H, Petersen CM, Roigaard H, Min HY, Vilhardt F, Moller LB, Kornfeld S, Gliemann J. Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J Cell Biol. 1998; 141: 815-828.
    CrossrefPubMedGoogle Scholar
  • 64 Godar S, Horejsi V, Weidle U, Binder BR, Hansmann C, Stockinger H. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-β1. Eur J Immunol. 1999; 29: 1-10.
    CrossrefPubMedGoogle Scholar
  • 65 Monier S, Parton RG, Vogel F, Behlke J, Henske A, Kurzchalia TV. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell. 1995; 6: 911-927.
    CrossrefPubMedGoogle Scholar
  • 66 Wary KK, Mariotti A, Zurzolo C, Giancotti FG. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell. 1998; 94: 625-634.
    CrossrefPubMedGoogle Scholar
  • 67 Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol. 1994; 126: 259-270.
    CrossrefPubMedGoogle Scholar
  • 68 Wang N, Planus E, Pouchelet M, Fredberg JJ, Barlovatz MG. Urokinase receptor mediates mechanical force transfer across the cell surface. Am J Physiol. 1995; 268: C1062-C1066.
    CrossrefPubMedGoogle Scholar
  • 69 Dumler I, Petri T, Schleuning WD. Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett. 1993; 322: 37-40.
    CrossrefPubMedGoogle Scholar
  • 70 Tang H, Kerins DM, Hao Q, Inagami T, Vaughan DE. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem. 1998; 273: 18268-18272.
    CrossrefPubMedGoogle Scholar
  • 71 Konakova M, Hucho F, Schleuning WD. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur J Biochem. 1998; 253: 421-429.
    CrossrefPubMedGoogle Scholar
  • 72 Anichini E, Fibbi G, Pucci M, Caldini R, Chevanne M, Del RM. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor. Exp Cell Res. 1994; 213: 438-448.
    CrossrefPubMedGoogle Scholar
  • 73 Li C, Liu JN, Gurewich V. Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. J Biol Chem. 1995; 270: 30282-30285.
    CrossrefPubMedGoogle Scholar
  • 74 van den Berg CW, Cinek T, Hallett MB, Horejsi V, Morgan BP. Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in membrane clusters on U937 cells and becomes Ca(2+)-signaling competent. J Cell Biol. 1995; 131: 669-677.
    CrossrefPubMedGoogle Scholar
  • 75 Dumler I, Petri T, Schleuning WD. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett. 1994; 343: 103-106.
    CrossrefPubMedGoogle Scholar
  • 76 Lu H, Mabilat C, Yeh P, Guitton JD, Li H, Pouchelet M, Shoevaert D, Legrand Y, Soria J, Soria C. Blockage of urokinase receptor reduces in vitro the motility and the deformability of endothelial cells. FEBS Lett. 1996; 380: 21-24.
    CrossrefPubMedGoogle Scholar
  • 77 Dear AE, Medcalf RL. Urokinase mediated induction of an interferon (IFN) responsive gene promoter may utilise IFN alpha-stimulated gene response elements (ISRE). Fibrinol Proteol. 1997; 11: 19a.
    PubMedGoogle Scholar
  • 78 Harder T, Scheiffele P, Verkade P, Simons K. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol. 1998; 141: 929-942.
    CrossrefPubMedGoogle Scholar
  • 79 Kenworthy AK, Edidin M. Distribution of a glycosylphosphatidylinositol-anchored protein at the apical surface of MDCK cells examined at a resolution of <100 A using imaging fluorescence resonance energy transfer. J Cell Biol. 1998; 142: 69-84.
    CrossrefPubMedGoogle Scholar
  • 80 Friedrichson T, Kurzchalia TV. Microdomains of GPI-anchored proteins in living cells revealed by crosslinking. Nature 1998; 394: 802-805.
    CrossrefPubMedGoogle Scholar
  • 81 Sheets ED, Lee GM, Simson R, Jacobson K. Transient confinement of a glycosylphosphatidylinositol-anchored protein in the plasma membrane. Biochemistry. 1997; 36: 12449-12458.
    CrossrefPubMedGoogle Scholar
  • 82 Schnitzer JE, McIntosh DP, Dvorak AM, Liu J, Oh P. Separation of caveolae from associated microdomains of GPI-anchored proteins [see comments]. Science 1995; 269: 1435-1439.
    CrossrefPubMedGoogle Scholar
  • 83 Stulnig TM, Berger M, Sigmund T, Stockinger H, Horejsi V, Waldhausl W. Signal transduction via glycosyl phosphatidylinositol-anchored proteins in T cells is inhibited by lowering cellular cholesterol. J Biol Chem. 1997; 272: 19242-19247.
    CrossrefPubMedGoogle Scholar
  • 84 Robinson PJ. Signal transduction by GPI-anchored membrane proteins. Cell Biol Int Rep. 1991; 15: 761-767.
    CrossrefPubMedGoogle Scholar